Publications by authors named "Schlessinger J"

Unlabelled: Focal adhesion kinase (FAK) functions as a signaling and scaffolding protein within endothelial cells (ECs) impacting blood vessel function and tumor growth. Interpretations of EC FAK-null phenotypes are complicated by related PYK2 (protein tyrosine kinase 2) expression, and to test this, we created PYK2 FAK mice with tamoxifen-inducible EC-specific Cre recombinase expression. At 11 weeks of age, EC FAK inactivation resulted in increased heart and lung mass and vascular leakage only on a PYK2 background.

View Article and Find Full Text PDF

Background: AbobotulinumtoxinA has become well established as a treatment option for moderate to severe glabellar lines since its first aesthetic approval in 2009.

Objective: Pivotal trials leading to regulatory approval showed that abobotulinumtoxinA treatment was associated with high responder rates when defined as achievement of none or mild glabellar lines (0 or 1 on the glabellar line severity scale) and a duration of action of up to 5 months. More recently, the goals for treatment of glabellar lines have shifted toward not only achieving a decrease in glabellar line severity but also ensuring that patients are satisfied with their experience.

View Article and Find Full Text PDF
Article Synopsis
  • Cendakimab is a treatment that targets and inhibits interleukin-13 (IL-13), which plays a role in the development of atopic dermatitis (AD), and is being studied for its effectiveness in treating this condition compared to a placebo.
  • A phase 2 clinical trial involved 221 adult participants with moderate to severe AD who had not responded well to topical treatments, with patients receiving different doses of cendakimab or a placebo from May 2021 to November 2022.
  • Results showed that the highest dose of cendakimab (720 mg, once weekly) significantly improved eczema symptoms compared to placebo, while other dosages did not achieve statistical significance, indicating potential for cend
View Article and Find Full Text PDF

Many growth factors and cytokines signal by binding to the extracellular domains of their receptors and driving association and transphosphorylation of the receptor intracellular tyrosine kinase domains, initiating downstream signaling cascades. To enable systematic exploration of how receptor valency and geometry affect signaling outcomes, we designed cyclic homo-oligomers with up to 8 subunits using repeat protein building blocks that can be modularly extended. By incorporating a de novo-designed fibroblast growth factor receptor (FGFR)-binding module into these scaffolds, we generated a series of synthetic signaling ligands that exhibit potent valency- and geometry-dependent Ca release and mitogen-activated protein kinase (MAPK) pathway activation.

View Article and Find Full Text PDF

High-grade neuroendocrine cervical cancers (NETc) are exceedingly rare, highly aggressive tumors. We analyzed 64 NETc tumor samples by whole-exome sequencing (WES). Human papillomavirus DNA was detected in 65.

View Article and Find Full Text PDF

Growth factors and cytokines signal by binding to the extracellular domains of their receptors and drive association and transphosphorylation of the receptor intracellular tyrosine kinase domains, initiating downstream signaling cascades. To enable systematic exploration of how receptor valency and geometry affects signaling outcomes, we designed cyclic homo-oligomers with up to 8 subunits using repeat protein building blocks that can be modularly extended. By incorporating a designed fibroblast growth-factor receptor (FGFR) binding module into these scaffolds, we generated a series of synthetic signaling ligands that exhibit potent valency- and geometry-dependent Ca2+ release and MAPK pathway activation.

View Article and Find Full Text PDF

Introduction: Uterine leiomyosarcomas (uLMS) are rare, highly aggressive tumors. Up to 30% of uLMS may harbor gain of function (GOF) in the MAP2K4 gene, important for tumor cell proliferation, differentiation and metastasis. We investigated the in vivo activity of a novel MAP2K4 inhibitor, PLX8725, against uLMS harboring MAP2K4 gene-amplification.

View Article and Find Full Text PDF
Article Synopsis
  • - The receptor tyrosine kinase KIT, along with its ligand stem cell factor (SCF), is essential for developing various cell types, and mutations in KIT are linked to several human cancers, like leukemia and gastrointestinal tumors.
  • - Cryo-electron microscopy studies reveal structural differences between normal and mutated forms of KIT, particularly in the extracellular domain, suggesting that the D5 region may be a critical target for new cancer therapies.
  • - Oncogenic KIT mutants show different conformations, with one mutant reverting to a wild-type structure upon SCF binding, highlighting the potential for drug development aimed at restoring or targeting these conformational changes.
View Article and Find Full Text PDF

While important insights were gained about how FGF21 and other endocrine fibroblast growth factors (FGFs) bind to Klotho proteins, the exact mechanism of Klotho/FGF receptor assembly that drives receptor dimerization and activation has not been elucidated. The prevailing dogma is that Klotho proteins substitute for the loss of heparan sulfate proteoglycan (HSPG) binding to endocrine FGFs by high-affinity binding of endocrine FGF molecules to Klotho receptors. To explore a potential role of HSPG in FGF21 signaling, we have analyzed the dynamic properties of FGF21-induced FGF21-βKlotho-FGFR1c complexes on the surface of living wild-type (WT) or HSPG-deficient Chinese hamster ovary (CHO) cells by employing quantitative single-molecule fluorescence imaging analyses.

View Article and Find Full Text PDF

The phosphoinositide-3 kinase (PI-3K)/AKT cell survival pathway is an important pathway activated by EGFR signaling. Here we show, that in addition to previously described critical components of this pathway, i.e.

View Article and Find Full Text PDF

Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic loop that does not occur in their JH1 domains.

View Article and Find Full Text PDF
Article Synopsis
  • - The study focuses on fibroblast growth factor receptors (FGFRs) and their regulated signaling processes, particularly the interaction between specific FGF ligands and two FGFR isoforms (b- and c-isoforms).
  • - Researchers have developed a mini-protein called mb7, designed to bind to the ligand-binding region of FGFR2, which shows high affinity for the c-isoform and inhibits its signaling from certain FGFs.
  • - Mb7 also blocks interactions between FGFRs and Klotho proteins, acting as an antagonist to metabolic hormones FGF19 and FGF21, which could lead to new therapeutic approaches for diseases linked to faulty FGFR activation.
View Article and Find Full Text PDF

JAK2 is a non-receptor tyrosine kinase that regulates hematopoiesis through the JAK-STAT pathway. The pseudokinase domain (JH2) is an important regulator of the activity of the kinase domain (JH1). V617F mutation in JH2 has been associated with the pathogenesis of various myeloproliferative neoplasms, but JAK2 JH2 has been poorly explored as a pharmacological target.

View Article and Find Full Text PDF

Background: Collagen-rich fibrous septae and subcutaneous adipose protrusions play a role in cellulite pathophysiology. Collagenase clostridium histolyticum-aaes (CCH-aaes) injection causes enzymatic release of septae to resolve cellulite depressions and create a skin smoothing effect. This analysis pooled data from two identically designed, phase-3, randomized, double-blind, placebo-controlled studies to examine the efficacy and safety of CCH-aaes.

View Article and Find Full Text PDF

The Janus kinase 2 (JAK2) pseudokinase domain (JH2) is an ATP-binding domain that regulates the activity of the catalytic tyrosine kinase domain (JH1). Dysregulation of JAK2 JH1 signaling caused by the V617F mutation in JH2 is implicated in various myeloproliferative neoplasms. To explore if JAK2 activity can be modulated by a small molecule binding to the ATP site in JH2, we have developed several ligand series aimed at selectively targeting the JAK2 JH2 domain.

View Article and Find Full Text PDF

Augmentor α and β (Augα and Augβ) are newly discovered ligands of the receptor tyrosine kinases Alk and Ltk. Augα functions as a dimeric ligand that binds with high affinity and specificity to Alk and Ltk. However, a monomeric Augα fragment and monomeric Augβ also bind to Alk and potently stimulate cellular responses.

View Article and Find Full Text PDF
Article Synopsis
  • Designing proteins that specifically bind to target sites based solely on the target's 3D structure is challenging, but the authors propose a new method that starts with a broad exploration of possible binding modes before focusing on the most promising ones.
  • They successfully created binding proteins for 12 different proteins, which are smaller than 65 amino acids and demonstrate strong binding affinities after optimization.
  • The study also resolved the crystal structures of five binder-target complexes, contributing valuable experimental data to improve our understanding of protein interactions and enhancing future designs for therapeutic and diagnostic use.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate a new hyaluronic acid gel with lidocaine for lip augmentation, comparing its safety and effectiveness against an existing product.
  • A total of 158 eligible participants underwent a double-blind, randomized trial, with efficacy measured over 6 months using various assessment methods.
  • Results showed that both products had similar effectiveness in improving lip fullness, and the new product received higher satisfaction rates among patients and investigators, indicating it is as safe and effective as the comparator.
View Article and Find Full Text PDF

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that regulates important functions in the central nervous system. The ALK gene is a hotspot for chromosomal translocation events that result in several fusion proteins that cause a variety of human malignancies. Somatic and germline gain-of-function mutations in ALK were identified in paediatric neuroblastoma.

View Article and Find Full Text PDF